RecruitingNot ApplicableNCT05066178

Speech Treatment for Minimally Verbal Children With ASD and CAS

Sponsor

MGH Institute of Health Professions

Enrollment

20 participants

Start Date

May 1, 2024

Study Type

INTERVENTIONAL

Conditions

Autism Spectrum Disorder Developmental Verbal Dyspraxia

Summary

Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.

Eligibility

Min Age: 5 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called CAS Treatment for Minimally Verbal Children with Autism for people with autism spectrum disorder and developmental verbal dyspraxia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 5 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.